Idogen AB
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment wi… Read more
Idogen AB (IDOGEN) - Net Assets
Latest net assets as of March 2023: Skr2.03 Million SEK
Based on the latest financial reports, Idogen AB (IDOGEN) has net assets worth Skr2.03 Million SEK as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr5.12 Million) and total liabilities (Skr3.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr2.03 Million |
| % of Total Assets | 39.71% |
| Annual Growth Rate | 0.56% |
| 5-Year Change | -92.92% |
| 10-Year Change | N/A |
| Growth Volatility | 107.49 |
Idogen AB - Net Assets Trend (2014–2022)
This chart illustrates how Idogen AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Idogen AB (2014–2022)
The table below shows the annual net assets of Idogen AB from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | Skr3.61 Million | -67.12% |
| 2021-12-31 | Skr10.99 Million | -72.95% |
| 2020-12-31 | Skr40.62 Million | +121.63% |
| 2019-12-31 | Skr18.33 Million | -64.08% |
| 2018-12-31 | Skr51.02 Million | +27.92% |
| 2017-12-31 | Skr39.89 Million | +114.49% |
| 2016-12-31 | Skr18.60 Million | +52.83% |
| 2015-12-31 | Skr12.17 Million | +252.38% |
| 2014-12-31 | Skr3.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Idogen AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4574304500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.10 Million | 141.25% |
| Other Components | Skr46.26 Million | 1280.73% |
| Total Equity | Skr3.61 Million | 100.00% |
Idogen AB Competitors by Market Cap
The table below lists competitors of Idogen AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ELEGANCE OPT.INT.HO.HD-10
F:5HW
|
$941.58K |
|
Argent
JSE:ART
|
$941.59K |
|
Advanced Health Intelligence Ltd.
OTCGREY:MYZQF
|
$942.63K |
|
Hempco Food and Fiber Inc
V:HEMP
|
$942.89K |
|
MicroStrategy Incorporated Variable Rate Series A Perpetual Stretch Preferred Stock
NASDAQ:STRC
|
$940.02K |
|
International Prospect Ventures Ltd
PINK:URANF
|
$939.82K |
|
CKALF
PINK:CKALF
|
$939.80K |
|
Strive, Inc. Variable Rate Series A Perpetual Preferred Stock
NYSE:SATA
|
$939.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Idogen AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 10,987,000 to 3,612,000, a change of -7,375,000 (-67.1%).
- Net loss of 47,608,000 reduced equity.
- New share issuances of 40,375,000 increased equity.
- Other factors decreased equity by 142,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-47.61 Million | -1318.05% |
| Share Issuances | Skr40.38 Million | +1117.8% |
| Other Changes | Skr-142.00K | -3.93% |
| Total Change | Skr- | -67.12% |
Book Value vs Market Value Analysis
This analysis compares Idogen AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.04x to 2.09x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr2.91 | Skr0.12 | x |
| 2015-12-31 | Skr10.25 | Skr0.12 | x |
| 2016-12-31 | Skr12.54 | Skr0.12 | x |
| 2017-12-31 | Skr13.60 | Skr0.12 | x |
| 2018-12-31 | Skr13.55 | Skr0.12 | x |
| 2019-12-31 | Skr3.18 | Skr0.12 | x |
| 2020-12-31 | Skr4.23 | Skr0.12 | x |
| 2021-12-31 | Skr0.57 | Skr0.12 | x |
| 2022-12-31 | Skr0.06 | Skr0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Idogen AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1318.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.49x
- Recent ROE (-1318.05%) is below the historical average (-247.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -56.54% | 0.00% | 0.00x | 1.15x | Skr-2.30 Million |
| 2015 | -79.37% | 0.00% | 0.00x | 1.09x | Skr-10.87 Million |
| 2016 | -67.75% | 0.00% | 0.00x | 1.11x | Skr-14.46 Million |
| 2017 | -53.46% | 0.00% | 0.00x | 1.11x | Skr-25.31 Million |
| 2018 | -54.16% | 0.00% | 0.00x | 1.40x | Skr-32.74 Million |
| 2019 | -178.38% | 0.00% | 0.00x | 1.70x | Skr-34.53 Million |
| 2020 | -66.03% | 0.00% | 0.00x | 1.25x | Skr-30.89 Million |
| 2021 | -353.65% | 0.00% | 0.00x | 2.10x | Skr-39.95 Million |
| 2022 | -1318.05% | 0.00% | 0.00x | 2.49x | Skr-47.97 Million |
Industry Comparison
This section compares Idogen AB's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
No peer company data available for comparison.